<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193089</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 46</org_study_id>
    <secondary_id>GIA 11180</secondary_id>
    <secondary_id>H2369n</secondary_id>
    <nct_id>NCT00193089</nct_id>
  </id_info>
  <brief_title>Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer</brief_title>
  <official_title>Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II trial we attempt to improve upon the efficacy of the trastuzumab/vinorelbine&#xD;
      combination by adding weekly docetaxel. When administered on a weekly schedule, docetaxel is&#xD;
      well tolerated with minimal myelosuppression, so that it is likely that fully efficacious&#xD;
      doses of all three drugs can be administered&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, all patients will be receive:&#xD;
&#xD;
      Trastuzumab + Vinorelbine + Docetaxel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility and toxicity of the combination of weekly docetaxel, vinorelbine, and trastuzumab in patients with metastatic breast cancer who overexpress Her-2.</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in this study, you must meet the following criteria:&#xD;
&#xD;
          -  Metastatic breast cancer confirmed by biopsy&#xD;
&#xD;
          -  Overexpression of the Her-2 oncogene&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Able to perform activities of daily living with minimal assistance&#xD;
&#xD;
          -  No previous chemotherapy for metastatic disease&#xD;
&#xD;
          -  One or more previous hormonal therapies for metastatic disease.&#xD;
&#xD;
          -  Adequate bone marrow, liver and kidney function&#xD;
&#xD;
          -  Patients with &lt; grade 1 peripheral neuropathy are eligible.&#xD;
&#xD;
          -  Must give written informed consent prior to entering this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        You cannot participate in this study if any of the following apply to you:&#xD;
&#xD;
          -  Abnormal heart function&#xD;
&#xD;
          -  Previous treatment with trastuzumab&#xD;
&#xD;
          -  Brain metastases untreated&#xD;
&#xD;
          -  Pre-existing symptomatic peripheral neuropathy&#xD;
&#xD;
          -  Serious underlying medical conditions&#xD;
&#xD;
        Please note: There are additional inclusion/exclusion criteria. The study center will&#xD;
        determine if you meet all of the criteria. If you do not qualify for the trial, study&#xD;
        personnel will explain the reasons. If you do qualify, study personnel will explain the&#xD;
        trial in detail and answer any questions you may have.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Hainsworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <results_reference>
    <citation>Infante JR, Yardley DA, Burris HA 3rd, Greco FA, Farley CP, Webb C, Spigel DR, Hainsworth JD. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer. 2009 Feb;9(1):23-8. doi: 10.3816/CBC.2009.n.004.</citation>
    <PMID>19299236</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

